ENTRADA THERAPEUTICS, INC. TRDA 深 滬
交易中 08-08 10:24:39 美东时间
5.33
+0.030
+0.57%
華盛通- 最 高5.457
- 今 開5.35
- 成交量 4.37万股
- 最 低 5.16
- 昨 收 5.30
- 總市值 2.02亿
- 52周最高 21.79
- 市盈率 靜 3.17
- 換手率 0.12%
- 52周最低 4.98
- 委 比 -33.44%
- 總股本 3795.34万
- 歷史最高 36.85
- 量 比 1.07
- 振 幅 5.60%
- 歷史最低 4.98
- 每 手 1
- 風險率 1.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Entrada Therapeutics Q2 EPS $(1.04) Misses $(0.85) Estimate, Sales $1.950M Miss $9.651M Estimate
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.85) by 22.64 percent. This is a 167.1 percent decrease over earnings of $1.55 per share
08-06 19:34
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
Entrada Therapeutics reported Q2 2025 financial results and highlighted key milestones, including the first patient dosed in the ELEVATE-44-201 study and initiation of ELEVATE-45-201. Multiple clinical trial sites in the U.K. and EU are activated. The company expanded its leadership team with Navid Khan, PhD, and Kiran Patki, MD, to support its growing pipeline. Cash reserves of $354 million are expected to fund operations into Q2 2027. Data from...
08-06 11:00
Entrada Therapeutics Appoints New Board Member
An announcement from Entrada Therapeutics Inc ( ($TRDA) ) is now available. On ...
06-03 19:28
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Entrada Therapeutics has appointed Maha Radhakrishnan, M.D., to its Board of Directors. Dr. Radhakrishnan brings extensive experience in global drug development, which will support Entrada's clinical progress, particularly in its Duchenne muscular dystrophy programs.
06-03 11:00
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics granted 23,820 RSUs to six new non-executive employees under its 2025 Inducement Equity Plan. The RSUs vest with 25% after one year and 6.25% quarterly thereafter, contingent on continued employment. The company focuses on developing intracellular therapeutics for neuromuscular and ocular diseases.
06-02 20:30
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Entrada Therapeutics has received EU authorization to initiate the ELEVATE-45-201 Phase 1/2 clinical trial for ENTR-601-45, targeting Duchenne muscular dystrophy (DMD) patients amenable to exon 45 skipping. The global study will assess safety, tolerability, and efficacy, with plans to begin in Q3 2025.EN
05-28 11:00
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $20 price target.
05-20 18:48
Entrada Therapeutics Q1 EPS $(0.42) Beats $(0.76) Estimate, Sales $20.56M Beat $10.17M Estimate
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.76) by 44.74 percent. This is a 161.76 percent decrease over earnings of $0.68 per share
05-08 19:16
美股大行评级 | 潜在涨幅778.38%！HC Wainwright & Co.上调BioLine Rx目标价至26美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1113752959213998081.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持BioLine Rx(BLRX)"买入"评级，目标价从9美元升至26美元</p> <p>• 德银：上调固特异轮胎橡胶(GT)评级至"买入"，目标价13美元</p> <p
04-01 09:48
